Additional Information Regarding the SEVITENSION Study

Por Ruilope, Luis
Publicado em 2014

Prospects for Renovascular Protection by More Aggressive Renin-Angiotensin System Control

Por Ruilope, Luis Miguel
Publicado em 2008

Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension

Por Ruilope, Luis M
Publicado em 2008

Renin-angiotensin system blockade: time for a reappraisal?

Por Ruilope, Luis M.
Publicado no Eur Heart J (2014)

Erratum to: The Fixed-Dose Combination of Olmesartan/Amlodipine Was Superior in Central Aortic Blood Pressure Reduction Compared with Perindopril/Amlodipine: A Randomized, Double-B...

Por Ruilope, Luis, Schaefer, Angie
Publicado em 2014

The Fixed-Dose Combination of Olmesartan/Amlodipine Was Superior in Central Aortic Blood Pressure Reduction Compared with Perindopril/Amlodipine: A Randomized, Double-Blind Trial i...

Por Ruilope, Luis, Schaefer, Angie
Publicado em 2013

Erratum to: The Fixed-Dose Combination of Olmesartan/Amlodipine Was Superior in Central Aortic Blood Pressure Reduction Compared with Perindopril/Amlodipine: A Randomized, Double-B...

Por Ruilope, Luis, Schaefer, Angie
Publicado no Adv Ther (2015)

Amlodipine and valsartan as components of a rational and effective fixed-dose combination

Por Waeber, Bernard, Ruilope, Luis M
Publicado em 2009

Treatment of Prehypertension in Diabetes and Metabolic Syndrome: What are the pros?

Por Segura, Julian, Ruilope, Luis M.
Publicado em 2009

Clinical utility of fixed-combination telmisartan–amlodipine in the treatment of hypertension

Por Segura, Julian, Ruilope, Luis M
Publicado em 2011

RAS Blockade for Every Diabetic Patient: Pro and Con

Por Ruilope, Luis M., Solini, Anna
Publicado em 2011

A review of the benefits of early treatment initiation with single-pill combinations of telmisartan with amlodipine or hydrochlorothiazide

Por Segura, Julian, Ruilope, Luis Miguel
Publicado em 2013

Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection

Por Díez, Javier, Ruilope, Luis M.
Publicado no Eur Heart J Cardiovasc Pharmacother (2016)

Cardiovascular risk reduction by reversing endothelial dysfunction:ARBs, ACE inhibitors, or both? Expectations from The ONTARGET Trial Programme

Por Ruilope, Luis Miguel, Redón, Josep, Schmieder, Roland
Publicado em 2007

Trandolapril/verapamil combination in hypertensive diabetic patients

Por García Donaire, José A, Ruilope, Luis M
Publicado em 2007

Recent advances in the management of hypertension

Por García-Donaire, José Antonio, Ruilope, Luis M
Publicado em 2010

Cardiovascular and Renal Links along the Cardiorenal Continuum

Por García-Donaire, José A., Ruilope, Luis M.
Publicado em 2011

The impact of antihypertensives on kidney disease

Por Marquez, Diego F, Ruiz-Hurtado, Gema, Ruilope, Luis
Publicado no F1000Res (2017)

Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia

Por Boccara, Franck, Dent, Ricardo, Ruilope, Luis, Valensi, Paul
Publicado no Adv Ther (2017)

Clinical Implications of the 2013 ESH/ESC Hypertension Guidelines: Targets, Choice of Therapy, and Blood Pressure Monitoring

Por Kjeldsen, Sverre E., Aksnes, Tonje A., Ruilope, Luis M.
Publicado em 2014